Sharekhan has given Buy recommendation for Divis Laboratories with a target price of Rs. 4810 in its research report issued on May 28, 2021

Sharekhan’s research report on Divis Laboratories

Divis reported yet another impressive performance for Q4FY2021 with results ahead of estimates. Sales for Q4 were up 28.7% yoy while PAT grew 50.4%. Expanded capacities commissioning coupled with a robust growth outlook could open up substantial growth opportunities for the company. Divis has identified new growth avenues which include shortlisting of next set of 10 molecules and pursuing opportunities in contrast media manufacturing, which could be the key growth drivers.


We maintain our Buy recommendation on Divis Laboratories Limited (Divis) with a revised PT of Rs. 4,810.